Global Coccidiosis Treatment Market

Coccidiosis Treatment Comprehensive Study by Type (Sulfadimethoxine, Sulfaguanidine, Furazolidone, Trimethoprim/Sulfonamide, Others), Application (Poultry, Dog, Fish, Cat, Cattle, Others), Consumption Mode (Injection, Oral), Source (Chemical, Natural) Players and Region - Global Market Outlook to 2027

Coccidiosis Treatment Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 3.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Coccidiosis Treatment Market Overview:
Coccidiosis is caused by Eimeria, which are single-celled parasites (protozoa) that have a simple life cycle in the gut. Anticoccidial medications are critical in preventing and treating coccidiosis. Weight loss, mild intermittent to severe diarrhea, feces containing blood or mucus, dehydration, and decreased breeding are all signs of coccidiosis, one of the most common parasite illnesses of farmed animals. As per latest study released by AMA Research, the Global Coccidiosis Treatment market is expected to see growth rate of 3.8%

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period-2027
Historical Period2017-2021
UnitValue (USD N)
High Growth MarketNorth America
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • Increase Risk of Coccidiosis Due to Environmental Factor and Issue Related to Hygiene
  • The rise in the Consumption Rate of Meat and Poultry Product

Roadblocks
  • Growing Resistance of the Pathogen, Expensive Treatment and Prevention Will Constrain the Coccidiosis Treatment Market

Opportunities
  • Increasing Concern Towards Animal Health and Maintaining Healthier Diet Will Propel the Coccidiosis Treatment Market
  • Increasing Number of Veterinary Hospitals and Improvement in Drug Quality will grow the Coccidiosis Treatment Market

Challenges
  • Less Availability of Raw Material and Limited Production of Drug will Hamper the Coccidiosis Treatment Market


Competitive Landscape:

Some of the key players profiled in the report are Elanco Animal Health (United States), Huvepharma (United States), Phibro Animal Health (United States), US Biologic (United States), Ceva Animal Health (France), Zoetis (United States), Impextraco (Belgium), Kemin Industries (United States), Merck Animal Health (United States) and Virbac SA (France). Additionally, following companies can also be profiled that are part of our coverage like Zydus Animal Health (India), Bioproperties Pty. Ltd. (Australia) and Qilu Animal Health Products Co. Ltd. (China). Analyst at AMA Research see United States Players to retain maximum share of Global Coccidiosis Treatment market by 2027. Considering Market by Consumption Mode, the sub-segment i.e. Injection will boost the Coccidiosis Treatment market. Considering Market by Source, the sub-segment i.e. Chemical will boost the Coccidiosis Treatment market.

Latest Market Insights:
On 04 June 2021, the US Department of Agriculture, Agriculture Research Service, and US Biologic Inc. has developed an Oral Antibiotic option for the treatment of chicken coccidiosis. The newly developed oral solution comes in the form of a probiotic powder that can be blended into existing feed procedures and provided to birds throughout their lives without needing any additional stages or components. This oral approach will significantly minimize the clinical impact of coccidiosis, reduce disease transmission, and enhance poultry gut health. This indicates that birds given NK-2 have a healthier gut and are less prone to illness. The technique has been patented by the USDA-ARS and US Biologic, and US Biologic has signed an exclusive global commercialization agreement with the objective of developing and licensing it for industrial usage.

On 01 Oct 2020, Huvepharma launch a new Coccidiosis control solution Monimax. Monimax is a mixture of two anticoccidials, nicarbazin and monensin, which operate in distinct ways. The ionophore monensin is poorly absorbed by epithelial cells. It will interact with the parasite when it is extracellular, mostly before it penetrates the epithelial cells, implying that it will have an early impact on the parasite's life cycle. Nicarbazin is efficiently absorbed by epithelial cells and has an intracellular interaction with the parasite. Nicarbazin affects the first and second stage schizonts and suppresses the parasite later in its life cycle. Because large dosages of nicarbazin can induce stress in birds, the combination of the two in Monimax reduces the risk of damage to birds.

What Can be Explored with the Coccidiosis Treatment Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Coccidiosis Treatment Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Coccidiosis Treatment
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Coccidiosis Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Coccidiosis Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Coccidiosis Treatment Manufactures, Coccidiosis Treatment Distributors and Suppliers, Research and Development Institutes, Upstream and Downstream Buyers, Financial Institutes and Investors, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Sulfadimethoxine
  • Sulfaguanidine
  • Furazolidone
  • Trimethoprim/Sulfonamide
  • Others
By Application
  • Poultry
  • Dog
  • Fish
  • Cat
  • Cattle
  • Others
By Consumption Mode
  • Injection
  • Oral

By Source
  • Chemical
  • Natural

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Risk of Coccidiosis Due to Environmental Factor and Issue Related to Hygiene
      • 3.2.2. The rise in the Consumption Rate of Meat and Poultry Product
    • 3.3. Market Challenges
      • 3.3.1. Less Availability of Raw Material and Limited Production of Drug will Hamper the Coccidiosis Treatment Market
    • 3.4. Market Trends
      • 3.4.1. Adoption of Latest Technologies and New Development of Drug for Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Coccidiosis Treatment, by Type, Application, Consumption Mode, Source and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Coccidiosis Treatment (Value)
      • 5.2.1. Global Coccidiosis Treatment by: Type (Value)
        • 5.2.1.1. Sulfadimethoxine
        • 5.2.1.2. Sulfaguanidine
        • 5.2.1.3. Furazolidone
        • 5.2.1.4. Trimethoprim/Sulfonamide
        • 5.2.1.5. Others
      • 5.2.2. Global Coccidiosis Treatment by: Application (Value)
        • 5.2.2.1. Poultry
        • 5.2.2.2. Dog
        • 5.2.2.3. Fish
        • 5.2.2.4. Cat
        • 5.2.2.5. Cattle
        • 5.2.2.6. Others
      • 5.2.3. Global Coccidiosis Treatment by: Consumption Mode (Value)
        • 5.2.3.1. Injection
        • 5.2.3.2. Oral
      • 5.2.4. Global Coccidiosis Treatment by: Source (Value)
        • 5.2.4.1. Chemical
        • 5.2.4.2. Natural
      • 5.2.5. Global Coccidiosis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Coccidiosis Treatment (Price)
      • 5.3.1. Global Coccidiosis Treatment by: Type (Price)
  • 6. Coccidiosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Elanco Animal Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Huvepharma (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Phibro Animal Health (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. US Biologic (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ceva Animal Health (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Zoetis (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Impextraco (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kemin Industries (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck Animal Health (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Virbac SA (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Coccidiosis Treatment Sale, by Type, Application, Consumption Mode, Source and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Coccidiosis Treatment (Value)
      • 7.2.1. Global Coccidiosis Treatment by: Type (Value)
        • 7.2.1.1. Sulfadimethoxine
        • 7.2.1.2. Sulfaguanidine
        • 7.2.1.3. Furazolidone
        • 7.2.1.4. Trimethoprim/Sulfonamide
        • 7.2.1.5. Others
      • 7.2.2. Global Coccidiosis Treatment by: Application (Value)
        • 7.2.2.1. Poultry
        • 7.2.2.2. Dog
        • 7.2.2.3. Fish
        • 7.2.2.4. Cat
        • 7.2.2.5. Cattle
        • 7.2.2.6. Others
      • 7.2.3. Global Coccidiosis Treatment by: Consumption Mode (Value)
        • 7.2.3.1. Injection
        • 7.2.3.2. Oral
      • 7.2.4. Global Coccidiosis Treatment by: Source (Value)
        • 7.2.4.1. Chemical
        • 7.2.4.2. Natural
      • 7.2.5. Global Coccidiosis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Coccidiosis Treatment (Price)
      • 7.3.1. Global Coccidiosis Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Coccidiosis Treatment: by Type(USD N)
  • Table 2. Coccidiosis Treatment Sulfadimethoxine , by Region USD N (2016-2021)
  • Table 3. Coccidiosis Treatment Sulfaguanidine , by Region USD N (2016-2021)
  • Table 4. Coccidiosis Treatment Furazolidone , by Region USD N (2016-2021)
  • Table 5. Coccidiosis Treatment Trimethoprim/Sulfonamide , by Region USD N (2016-2021)
  • Table 6. Coccidiosis Treatment Others , by Region USD N (2016-2021)
  • Table 7. Coccidiosis Treatment: by Application(USD N)
  • Table 8. Coccidiosis Treatment Poultry , by Region USD N (2016-2021)
  • Table 9. Coccidiosis Treatment Dog , by Region USD N (2016-2021)
  • Table 10. Coccidiosis Treatment Fish , by Region USD N (2016-2021)
  • Table 11. Coccidiosis Treatment Cat , by Region USD N (2016-2021)
  • Table 12. Coccidiosis Treatment Cattle , by Region USD N (2016-2021)
  • Table 13. Coccidiosis Treatment Others , by Region USD N (2016-2021)
  • Table 14. Coccidiosis Treatment: by Consumption Mode(USD N)
  • Table 15. Coccidiosis Treatment Injection , by Region USD N (2016-2021)
  • Table 16. Coccidiosis Treatment Oral , by Region USD N (2016-2021)
  • Table 17. Coccidiosis Treatment: by Source(USD N)
  • Table 18. Coccidiosis Treatment Chemical , by Region USD N (2016-2021)
  • Table 19. Coccidiosis Treatment Natural , by Region USD N (2016-2021)
  • Table 20. South America Coccidiosis Treatment, by Country USD N (2016-2021)
  • Table 21. South America Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 22. South America Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 23. South America Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 24. South America Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 25. Brazil Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 26. Brazil Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 27. Brazil Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 28. Brazil Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 29. Argentina Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 30. Argentina Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 31. Argentina Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 32. Argentina Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 33. Rest of South America Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 34. Rest of South America Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 35. Rest of South America Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 36. Rest of South America Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 37. Asia Pacific Coccidiosis Treatment, by Country USD N (2016-2021)
  • Table 38. Asia Pacific Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 39. Asia Pacific Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 40. Asia Pacific Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 41. Asia Pacific Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 42. China Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 43. China Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 44. China Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 45. China Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 46. Japan Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 47. Japan Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 48. Japan Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 49. Japan Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 50. India Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 51. India Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 52. India Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 53. India Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 54. South Korea Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 55. South Korea Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 56. South Korea Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 57. South Korea Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 58. Taiwan Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 59. Taiwan Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 60. Taiwan Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 61. Taiwan Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 62. Australia Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 63. Australia Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 64. Australia Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 65. Australia Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 66. Rest of Asia-Pacific Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 67. Rest of Asia-Pacific Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 68. Rest of Asia-Pacific Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 69. Rest of Asia-Pacific Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 70. Europe Coccidiosis Treatment, by Country USD N (2016-2021)
  • Table 71. Europe Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 72. Europe Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 73. Europe Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 74. Europe Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 75. Germany Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 76. Germany Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 77. Germany Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 78. Germany Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 79. France Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 80. France Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 81. France Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 82. France Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 83. Italy Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 84. Italy Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 85. Italy Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 86. Italy Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 87. United Kingdom Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 88. United Kingdom Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 89. United Kingdom Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 90. United Kingdom Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 91. Netherlands Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 92. Netherlands Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 93. Netherlands Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 94. Netherlands Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 95. Rest of Europe Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 96. Rest of Europe Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 97. Rest of Europe Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 98. Rest of Europe Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 99. MEA Coccidiosis Treatment, by Country USD N (2016-2021)
  • Table 100. MEA Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 101. MEA Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 102. MEA Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 103. MEA Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 104. Middle East Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 105. Middle East Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 106. Middle East Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 107. Middle East Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 108. Africa Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 109. Africa Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 110. Africa Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 111. Africa Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 112. North America Coccidiosis Treatment, by Country USD N (2016-2021)
  • Table 113. North America Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 114. North America Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 115. North America Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 116. North America Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 117. United States Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 118. United States Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 119. United States Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 120. United States Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 121. Canada Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 122. Canada Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 123. Canada Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 124. Canada Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 125. Mexico Coccidiosis Treatment, by Type USD N (2016-2021)
  • Table 126. Mexico Coccidiosis Treatment, by Application USD N (2016-2021)
  • Table 127. Mexico Coccidiosis Treatment, by Consumption Mode USD N (2016-2021)
  • Table 128. Mexico Coccidiosis Treatment, by Source USD N (2016-2021)
  • Table 129. Coccidiosis Treatment: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Coccidiosis Treatment: by Type(USD N)
  • Table 141. Coccidiosis Treatment Sulfadimethoxine , by Region USD N (2022-2027)
  • Table 142. Coccidiosis Treatment Sulfaguanidine , by Region USD N (2022-2027)
  • Table 143. Coccidiosis Treatment Furazolidone , by Region USD N (2022-2027)
  • Table 144. Coccidiosis Treatment Trimethoprim/Sulfonamide , by Region USD N (2022-2027)
  • Table 145. Coccidiosis Treatment Others , by Region USD N (2022-2027)
  • Table 146. Coccidiosis Treatment: by Application(USD N)
  • Table 147. Coccidiosis Treatment Poultry , by Region USD N (2022-2027)
  • Table 148. Coccidiosis Treatment Dog , by Region USD N (2022-2027)
  • Table 149. Coccidiosis Treatment Fish , by Region USD N (2022-2027)
  • Table 150. Coccidiosis Treatment Cat , by Region USD N (2022-2027)
  • Table 151. Coccidiosis Treatment Cattle , by Region USD N (2022-2027)
  • Table 152. Coccidiosis Treatment Others , by Region USD N (2022-2027)
  • Table 153. Coccidiosis Treatment: by Consumption Mode(USD N)
  • Table 154. Coccidiosis Treatment Injection , by Region USD N (2022-2027)
  • Table 155. Coccidiosis Treatment Oral , by Region USD N (2022-2027)
  • Table 156. Coccidiosis Treatment: by Source(USD N)
  • Table 157. Coccidiosis Treatment Chemical , by Region USD N (2022-2027)
  • Table 158. Coccidiosis Treatment Natural , by Region USD N (2022-2027)
  • Table 159. South America Coccidiosis Treatment, by Country USD N (2022-2027)
  • Table 160. South America Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 161. South America Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 162. South America Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 163. South America Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 164. Brazil Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 165. Brazil Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 166. Brazil Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 167. Brazil Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 168. Argentina Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 169. Argentina Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 170. Argentina Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 171. Argentina Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 172. Rest of South America Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 173. Rest of South America Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 174. Rest of South America Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 175. Rest of South America Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 176. Asia Pacific Coccidiosis Treatment, by Country USD N (2022-2027)
  • Table 177. Asia Pacific Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 178. Asia Pacific Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 179. Asia Pacific Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 180. Asia Pacific Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 181. China Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 182. China Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 183. China Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 184. China Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 185. Japan Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 186. Japan Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 187. Japan Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 188. Japan Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 189. India Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 190. India Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 191. India Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 192. India Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 193. South Korea Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 194. South Korea Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 195. South Korea Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 196. South Korea Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 197. Taiwan Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 198. Taiwan Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 199. Taiwan Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 200. Taiwan Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 201. Australia Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 202. Australia Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 203. Australia Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 204. Australia Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 205. Rest of Asia-Pacific Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 206. Rest of Asia-Pacific Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 207. Rest of Asia-Pacific Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 208. Rest of Asia-Pacific Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 209. Europe Coccidiosis Treatment, by Country USD N (2022-2027)
  • Table 210. Europe Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 211. Europe Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 212. Europe Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 213. Europe Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 214. Germany Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 215. Germany Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 216. Germany Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 217. Germany Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 218. France Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 219. France Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 220. France Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 221. France Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 222. Italy Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 223. Italy Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 224. Italy Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 225. Italy Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 226. United Kingdom Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 227. United Kingdom Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 228. United Kingdom Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 229. United Kingdom Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 230. Netherlands Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 231. Netherlands Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 232. Netherlands Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 233. Netherlands Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 234. Rest of Europe Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 235. Rest of Europe Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 236. Rest of Europe Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 237. Rest of Europe Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 238. MEA Coccidiosis Treatment, by Country USD N (2022-2027)
  • Table 239. MEA Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 240. MEA Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 241. MEA Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 242. MEA Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 243. Middle East Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 244. Middle East Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 245. Middle East Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 246. Middle East Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 247. Africa Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 248. Africa Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 249. Africa Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 250. Africa Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 251. North America Coccidiosis Treatment, by Country USD N (2022-2027)
  • Table 252. North America Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 253. North America Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 254. North America Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 255. North America Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 256. United States Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 257. United States Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 258. United States Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 259. United States Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 260. Canada Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 261. Canada Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 262. Canada Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 263. Canada Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 264. Mexico Coccidiosis Treatment, by Type USD N (2022-2027)
  • Table 265. Mexico Coccidiosis Treatment, by Application USD N (2022-2027)
  • Table 266. Mexico Coccidiosis Treatment, by Consumption Mode USD N (2022-2027)
  • Table 267. Mexico Coccidiosis Treatment, by Source USD N (2022-2027)
  • Table 268. Coccidiosis Treatment: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Coccidiosis Treatment: by Type USD N (2016-2021)
  • Figure 5. Global Coccidiosis Treatment: by Application USD N (2016-2021)
  • Figure 6. Global Coccidiosis Treatment: by Consumption Mode USD N (2016-2021)
  • Figure 7. Global Coccidiosis Treatment: by Source USD N (2016-2021)
  • Figure 8. South America Coccidiosis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Coccidiosis Treatment Share (%), by Country
  • Figure 10. Europe Coccidiosis Treatment Share (%), by Country
  • Figure 11. MEA Coccidiosis Treatment Share (%), by Country
  • Figure 12. North America Coccidiosis Treatment Share (%), by Country
  • Figure 13. Global Coccidiosis Treatment: by Type USD/Units (2016-2021)
  • Figure 14. Global Coccidiosis Treatment share by Players 2021 (%)
  • Figure 15. Global Coccidiosis Treatment share by Players (Top 3) 2021(%)
  • Figure 16. Global Coccidiosis Treatment share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Elanco Animal Health (United States) Revenue, Net Income and Gross profit
  • Figure 19. Elanco Animal Health (United States) Revenue: by Geography 2021
  • Figure 20. Huvepharma (United States) Revenue, Net Income and Gross profit
  • Figure 21. Huvepharma (United States) Revenue: by Geography 2021
  • Figure 22. Phibro Animal Health (United States) Revenue, Net Income and Gross profit
  • Figure 23. Phibro Animal Health (United States) Revenue: by Geography 2021
  • Figure 24. US Biologic (United States) Revenue, Net Income and Gross profit
  • Figure 25. US Biologic (United States) Revenue: by Geography 2021
  • Figure 26. Ceva Animal Health (France) Revenue, Net Income and Gross profit
  • Figure 27. Ceva Animal Health (France) Revenue: by Geography 2021
  • Figure 28. Zoetis (United States) Revenue, Net Income and Gross profit
  • Figure 29. Zoetis (United States) Revenue: by Geography 2021
  • Figure 30. Impextraco (Belgium) Revenue, Net Income and Gross profit
  • Figure 31. Impextraco (Belgium) Revenue: by Geography 2021
  • Figure 32. Kemin Industries (United States) Revenue, Net Income and Gross profit
  • Figure 33. Kemin Industries (United States) Revenue: by Geography 2021
  • Figure 34. Merck Animal Health (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck Animal Health (United States) Revenue: by Geography 2021
  • Figure 36. Virbac SA (France) Revenue, Net Income and Gross profit
  • Figure 37. Virbac SA (France) Revenue: by Geography 2021
  • Figure 38. Global Coccidiosis Treatment: by Type USD N (2022-2027)
  • Figure 39. Global Coccidiosis Treatment: by Application USD N (2022-2027)
  • Figure 40. Global Coccidiosis Treatment: by Consumption Mode USD N (2022-2027)
  • Figure 41. Global Coccidiosis Treatment: by Source USD N (2022-2027)
  • Figure 42. South America Coccidiosis Treatment Share (%), by Country
  • Figure 43. Asia Pacific Coccidiosis Treatment Share (%), by Country
  • Figure 44. Europe Coccidiosis Treatment Share (%), by Country
  • Figure 45. MEA Coccidiosis Treatment Share (%), by Country
  • Figure 46. North America Coccidiosis Treatment Share (%), by Country
  • Figure 47. Global Coccidiosis Treatment: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Elanco Animal Health (United States)
  • Huvepharma (United States)
  • Phibro Animal Health (United States)
  • US Biologic (United States)
  • Ceva Animal Health (France)
  • Zoetis (United States)
  • Impextraco (Belgium)
  • Kemin Industries (United States)
  • Merck Animal Health (United States)
  • Virbac SA (France)
Additional players considered in the study are as follows:
Zydus Animal Health (India) , Bioproperties Pty. Ltd. (Australia) , Qilu Animal Health Products Co. Ltd. (China)
Select User Access Type

Key Highlights of Report


Jul 2022 208 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Coccidiosis Treatment Market Quantitative research analysis
Global Coccidiosis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Coccidiosis Treatment market are Elanco Animal Health (United States), Huvepharma (United States), Phibro Animal Health (United States), US Biologic (United States), Ceva Animal Health (France), Zoetis (United States), Impextraco (Belgium), Kemin Industries (United States), Merck Animal Health (United States) and Virbac SA (France), to name a few.
"Adoption of Latest Technologies and New Development of Drug for Treatment" is seen as one of major influencing trends for Coccidiosis Treatment Market during projected period 2021-2027.
Sulfadimethoxine segment in Global market to hold robust market share owing to "Increase Risk of Coccidiosis Due to Environmental Factor and Issue Related to Hygiene ".
dominated the Coccidiosis Treatment market. This is attributable to growing trend of "Adoption of Latest Technologies and New Development of Drug for Treatment"

Know More About Global Coccidiosis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Scleroderma Therapy Comprehensive Study by Type (Immunosuppressors, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors - PHA, Calcium Channel Blockers, Analgesic, Prostacyclin Analogues,...
$ 3650
Vaccine Shippers Comprehensive Study by Type (Insulated Shippers, Insulated Containers, Refrigerants), Application (Pharma, Biopharma), Type (Active Systems, Passive Systems), Usability Type (Single,...
$ 3500
Serum Lactate Testing Comprehensive Study by Application (Hospitals, Clinics, Home Care, Others), Indication (Sepsis, Heart attack, Congestive heart failure, Respiratory failure, Severe Anaemia Liver...
$ 3750
5HT3 Receptor Antagonists Comprehensive Study by Type (Ondansetron, Granisetron, Dolasetron, Palonosetron), Indication (Post-Operative Induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiti...
$ 3750
Chemotherapy-Induced Acral Erythema Comprehensive Study by Type (Analgesics, Anti-Inflammatory and Anti-Edematous Agents, Antihistaminic, NSAIDs, Oral/Topical Glucocorticoids, Pyridoxine (Vitamin B6)...
$ 3750
In Vitro Fertilization Test Comprehensive Study by Type (Ovarian Reserve Testing, Semen Analysis, Infectious Disease Screening, Practice (Mock) Embryo Transfer, Uterine Exam) Players and Region - Glo...
$ 3500